Eli Lilly and Company (LLY)
LLYNYSEBiotechnology: Pharmaceutical Preparations
$1,411.99
+57.99 (+4.28%) today
At the close, Nov 9, 4:03 PM ET. After hours $1,411.99 -0.02%
- Market cap
- $1.33tn
- P/E
- 44.2
- EPS, last 4 quarters
- $31.95
- Dividend yield
- –
- Day range
- $1,364.58 to $1,419.50
- 52-week range
- $850.51 to $1,453.00
- Average volume
- 3.41m
- Previous close
- $1,354.00
Analysts
24 coveringBuy22 buy, 1 hold, 1 sell
Targets a year out average $1,515.22, +7.3% from here
Earnings
next estimate $10.77Next report
Dec 2025
+7.9%
Mar 2026
+21.1%
Jun 2026
+39.4%
Sep 2026
+39.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $19.29bn | $19.80bn | $22.97bn | $24.40bn |
| Gross profit | $15.92bn | $16.22bn | $19.71bn | $20.46bn |
| Operating income | $8.38bn | $8.91bn | $8.98bn | $8.61bn |
| Net income | $6.64bn | $7.40bn | $7.09bn | $6.45bn |
Last four quarters: revenue $86.46bn, margin 31.9%, free cash flow $19.66bn
News
8 latest- Eli Lilly's Foundayo Cuts Sleep Apnea Severity By Up To 44% In Phase 3 Trials RTTNews · 4 hours ago
- Eli Lilly Moves Up In Analyst Rankings, Passing Williams BNK Invest · 4 hours ago
- S&P 500 Analyst Moves: LLY BNK Invest · 4 hours ago
- FDA Orders New Eye Risk Warnings For GLP-1 Drugs Such As Ozempic, Wegovy And Zepbound RTTNews · 5 hours ago
- Foundayo Cuts Sleep Apnea Severity By Up To 44% In Phase 3 Study, Lilly Eyes FDA Filing RTTNews · 6 hours ago
- Novo Up 4% in a Month: How Should Investors Approach the Stock Now?Zacks · 8 hours ago
- 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026Zacks · 9 hours ago
- Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.The Motley Fool · 10 hours ago
The company
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- Region
- North America
- Website
- lilly.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.